No CrossRef data available.
Published online by Cambridge University Press: 02 July 2020
We have described previously the presence of IL2R on human carcinoma (CA) cell lines (squamous cell carcinoma of the head and neck, gastric carcinoma, renal cell carcinoma) and tumors in situ (1,2,). These carcinomas expressed IL2Rβ and γ (intermediate affinity IL2R) and I-labeled IL2 was found to bind to these receptors. Scatchard analyses showed that 13,500 IL2Rβ/cell and about 300 IL2Rα were present on the surface of PCI-1, a SCCHN cell line. The mRNA and proteins for IL2Rβ and γ were consistently detectable in tumor cell lines and fresh tumor tissues. Binding of recombinant IL2 to IL2R resulted in a partial but significant inhibition of tumor cell growth, decreased expression of class I MHC antigens and ICAM-1 on tumor cells and their increased sensitivity to growth-modulating cytokines IFN-γ, TNF-α or TGFβ. These effects were IL2-dose dependent, and were optimal at doses >10nM. Anti-IL2Rβ Abs reversed IL2-induced growth inhibition, an indication that exogenous IL2 delivered a negative growth signal to CAs via the β chain of IL2R.